中文

ABOUT US

Our Company Management Team
Overview
Degron Therapeutics aims to become a global leader in the discovery and development of a new class of targeted protein degradation therapeutics, small molecule molecular glue degrader (MGD) drugs. Degron has assembled a team of world-class executives and scientific leaders, bringing its scientific excellence to the identification and validation of disease targets, particularly those undruggable by conventional small molecule inhibitors, and novel selective MGD compounds to meet unmet medical needs in all therapeutic areas.
Focus
Molecular glue protein degradation
platform to discover novel drugs
Unmet Need
About 80% of disease targets are
"undruggable" by existing technologies
Our solution
Innovative molecular glue degraders to drug
the "undruggable" targets and bring a new class
of treatment for various diseases

2021

2021

Founded in 2021
Professional and Dedicated

$34.5M

$34.5M

Raised from blue chip venture capital investors

20+

20+

Molecular glue discovery platform accelerating a broad pipeline of more than 20 projects

40+

40+

In vitro and in vivo target discovery and validation techniques